URGENT: This Altcoin Opportunity Won’t Wait – Act Now

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Anila Lingamneni net worth and biography

Anila Lingamneni Biography and Net Worth

EVP of Haemonetics

Anila Lingamneni serves as Executive Vice President, Chief Technology Officer of the Company. Prior to joining the Company, Ms. Lingamneni previously served as Vice President, Renal R&D at Baxter International from February 2017 to March 2020, where she was responsible for the product portfolio delivering renal therapy solutions to dialysis patients, including devices, software, disposables and fluids. In this role, she led a globally distributed team of engineers and scientists to drive long-term product roadmap definition and therapy innovation and delivered critical product launches. From May 2013 to January 2017, Ms. Lingamneni also served as Vice President, Device Engineering at Baxter International, where she was responsible for all electromechanical devices and software applications for Baxter's medical device portfolio, including infusion systems, compounding systems, renal peritoneal and hemodialysis systems and acute renal therapy systems. Before joining Baxter, Ms. Lingamneni held several roles at General Electric Healthcare, including Chief Technology Officer of the X-Ray Diagnostic Imaging Business Unit. Ms. Lingamneni received a Bachelor of Science in Electrical and Electronics Engineering and a Master of Science in Mathematics from Birla Institute of Technology and Science in India, and she earned a Master of Science in Biomedical Engineering from Iowa State University.

What is Anila Lingamneni's net worth?: The estimated net worth of Anila Lingamneni is at least $1.69 million as of July 11th, 2024. Ms. Lingamneni owns 21,410 shares of Haemonetics stock worth more than $1,686,466 as of December 19th. This net worth approximation does not reflect any other investments that Ms. Lingamneni may own. Additionally, Ms. Lingamneni receives a salary of $1,090,000.00 as EVP at Haemonetics. Learn More about Anila Lingamneni's net worth.
How old is Anila Lingamneni?: Ms. Lingamneni is currently 56 years old. There are 5 older executives and no younger executives at Haemonetics. The oldest executive at Haemonetics is Mr. Josep Lluis Llorens, Executive Vice President of Global Manufacturing & Supply Chain, who is 62 years old. Learn More on Anila Lingamneni's age.
What is Anila Lingamneni's salary?: As the EVP of Haemonetics Co., Ms. Lingamneni earns $1,090,000.00 per year. There are 3 executives that earn more than Ms. Lingamneni. The highest earning executive at Haemonetics is Mr. Christopher A. Simon, CEO, President & Director, who commands a salary of $3,260,000.00 per year. Learn More on Anila Lingamneni's salary.
How do I contact Anila Lingamneni?: The corporate mailing address for Ms. Lingamneni and other Haemonetics executives is 125 Summer Street, Boston MA, 02110. Haemonetics can also be reached via phone at (781) 848-7100 and via email at [email protected]. Learn More on Anila Lingamneni's contact information.
Has Anila Lingamneni been buying or selling shares of Haemonetics?: Anila Lingamneni has not been actively trading shares of Haemonetics during the last ninety days. Most recently, Anila Lingamneni sold 2,136 shares of the business's stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $90.00, for a transaction totalling $192,240.00. Following the completion of the sale, the executive vice president now directly owns 21,410 shares of the company's stock, valued at $1,926,900. Learn More on Anila Lingamneni's trading history.
Who are Haemonetics' active insiders?: Haemonetics' insider roster includes Michelle Basil (EVP), William Burke (CFO), Dan Goldstein (VP), Mark Kroll (Director), Anila Lingamneni (EVP), Josep Llorens (EVP), Richard Meelia (Director), Laurie Miller (SVP), Jacqueline Scanlan (SVP), Christopher Simon (CEO, President & Director), and Stewart Strong (Insider). Learn More on Haemonetics' active insiders.
Are insiders buying or selling shares of Haemonetics?: During the last twelve months, insiders at the medical instruments supplier sold shares 9 times. They sold a total of 33,828 shares worth more than $3,031,094.99. The most recent insider tranaction occured on July, 26th when insider Stewart W Strong sold 4,312 shares worth more than $393,038.80. Insiders at Haemonetics own 1.8% of the company. Learn More about insider trades at Haemonetics.
Information on this page was last updated on 7/26/2024.

Anila Lingamneni Insider Trading History at Haemonetics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/11/2024	Sell	2,136	$90.00	$192,240.00	21,410
5/6/2024	Sell	2,305	$95.00	$218,975.00	12,295
9/11/2023	Sell	2,305	$90.00	$207,450.00	14,495
5/30/2023	Sell	2,304	$83.33	$191,992.32	16,800
4/18/2022	Sell	189	$56.55	$10,687.95	14,013
5/19/2021	Sell	92	$55.19	$5,077.48
4/16/2021	Sell	170	$119.44	$20,304.80

Anila Lingamneni Buying and Selling Activity at Haemonetics

Haemonetics Company Overview

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $78.77

$78.26

$82.27

50 Day Range

MA: $81.32

$71.15

$93.38

2 Week Range

Now: $78.77

$70.25

$97.97

Volume

518,622 shs

Average Volume

551,348 shs

Market Capitalization

$3.96 billion

P/E Ratio

32.68

Dividend Yield

N/A

Beta

0.38

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

Anila Lingamneni Biography and Net Worth

What is Anila Lingamneni's net worth?

How old is Anila Lingamneni?

What is Anila Lingamneni's salary?

How do I contact Anila Lingamneni?

Has Anila Lingamneni been buying or selling shares of Haemonetics?

Who are Haemonetics' active insiders?

Are insiders buying or selling shares of Haemonetics?